Related references
Note: Only part of the references are listed.Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Xingcheng Yang et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)
Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker
Kenneth Emancipator
AAPS JOURNAL (2021)
Immune checkpoint inhibitors in acute myeloid leukemia
Naval Daver
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2021)
Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia
Lu Tang et al.
CLINICAL CANCER RESEARCH (2020)
PD-L1 Is Expressed and Promotes the Expansion of Regulatory T Cells in Acute Myeloid Leukemia
Yuqing Dong et al.
FRONTIERS IN IMMUNOLOGY (2020)
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
Leilei Ai et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
Piao Li et al.
JOURNAL OF IMMUNOLOGY (2019)
Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia
Krzysztof Giannopoulos
JOURNAL OF CLINICAL MEDICINE (2019)
High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations
Barbora Brodska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
Patrick Williams et al.
CANCER (2019)
JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
Alessandro Prestipino et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines
Toshifumi Doi et al.
ONCOLOGY REPORTS (2017)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML)
Naval Daver et al.
BLOOD (2016)
Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment
Holger Kroenig et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Myeloid leukemia cells with a B7-2+ subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands
Yusuf Dolen et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors
Celine Berthon et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells
Wei Ge et al.
LEUKEMIA RESEARCH (2009)
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
Daniela Pietra et al.
BLOOD (2008)
JAK2-V617F activating mutation in acute myeloid leukemia:: prognostic impact and association with other molecular markers
C. Vicente et al.
LEUKEMIA (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Share Paper
